Sumitomo Dainippon

Sumitomo merges U.S. biotechs to create oncology division
Fierce Biotech
Wed, 07/1/20 - 11:04 am
Sumitomo Dainippon
Tolero Pharmaceuticals
Boston Biomedical
oncology
M&A
For The First Time Ever, A Drug Developed By AI Will Be Tested In Human Trials
Forbes
Tue, 02/11/20 - 11:49 pm
artificial intelligence
OCD
drug development
DSP-1181
Sumitomo Dainippon
Exscientia
Top Biopharma M&As in 2019
BioSpace
Fri, 01/3/20 - 10:06 am
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
The Roivant-Sumitomo Deal: $3 Billion, 5 Companies, $550 Million in Loans and an Option on 6 More...
BioSpace
Fri, 11/1/19 - 06:57 pm
M&A
Roivant
Vivek Ramaswamy
Sumitomo Dainippon
Vivek Ramaswamy trades top execs and adds stealthy vant to $3B sale, while his new partner tosses Myovant $350M
Endpoints
Thu, 10/31/19 - 10:50 am
Vivek Ramaswamy
Sumitomo Dainippon
Myovant
Roivant lines up $3B upfront in Sumitomo Dainippon deal
Fierce Biotech
Fri, 09/6/19 - 10:16 am
M&A
Roivant
Sumitomo Dainippon
In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal
Endpoints
Mon, 10/30/17 - 11:05 am
Sumitomo Dainippon
diabetes
clinical trials
imeglimin
Poxel
Japanese pharma snaps up cancer biotech Tolero
BioPharma Dive
Fri, 12/23/16 - 10:03 am
Japan
Tolero Pharmaceuticals
M&A
Sumitomo Dainippon
Looking ahead at orphan drugs' future: More breakthroughs, exploding sales
BioPharma Dive
Wed, 02/17/16 - 09:49 pm
orphan drugs
Sumitomo Dainippon
obeticholic acid
AbbVie
venetoclax
Actelion
Uptravi
Intercept's much-hyped NASH drug misses the mark in Phase II
Fierce Biotech
Wed, 10/28/15 - 09:23 am
Intercept Pharmaceuticals
NASH
Sumitomo Dainippon
Japan
OCA